dc.contributor.author | Saydam, Guray | |
dc.contributor.author | Haznedaroglu, Ibrahim C. | |
dc.contributor.author | Temiz, Yesim | |
dc.contributor.author | Soysal, Teoman | |
dc.contributor.author | Sucak, Gulsan | |
dc.contributor.author | Tombuloglu, Murat | |
dc.contributor.author | Ozdogu, Hakan | |
dc.contributor.author | Yavuz, Selim | |
dc.contributor.author | Altintas, Abdullah | |
dc.contributor.author | Ozet, Gulsum | |
dc.contributor.author | Gulbas, Zafer | |
dc.contributor.author | Ferhanoglu, Burhan | |
dc.contributor.author | Ilhan, Osman | |
dc.date.accessioned | 2019-12-10T11:20:22Z | |
dc.date.available | 2019-12-10T11:20:22Z | |
dc.date.issued | 2009 | |
dc.identifier.issn | 1306-133X | |
dc.identifier.uri | https://doi.org/ | |
dc.identifier.uri | http://hdl.handle.net/11655/15321 | |
dc.description.abstract | This retrospective study was conducted on 114 CML patients with a mean treatment duration of 7.94 +/- 4.53 months. Disease status distribution among patients was 78.1% in chronic, 7.9% in accelerated, 14% in blastic phases. The last imatinib doses in chronic, accelerated and blastic phases were 609.72 +/- 171.29, 714.29 +/- 106.90, and 569.23 +/- 160.13, respectively. Complete hematologic response was 66.3% and 44.4% in chronic and accelerated phases, respectively. Molecular response was evaluated by bcr/abl transcript levels in RT-PCR. Complete molecular response was 27.0% in chronic, 11.1% in accelerated and 18.8% in blastic phases. Of 99 patients 77 (77.8%) were alive. 16th month-OS for 99 patients was 78% in Kaplan-Meier survival analysis. No adverse event was reported in 69.2% of patients, whereas disease progression and grade 1-2 myelosupression were the most frequently reported events. Most patients had complete hematological response. Dasatinib treatment was well-tolerated and resulted in favorable outcomes with mostly mild side effects. | |
dc.language.iso | en | |
dc.publisher | Akad Doktorlar Yayınevi | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Oncology | |
dc.title | Retrospective Evaluation of Patients Treated with Dasatinib For Philadelphia Positive Leukemias: Turkish Experience of 16 Months | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi | |
dc.contributor.department | İç Hastalıkları | |
dc.identifier.volume | 19 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 195 | |
dc.identifier.endpage | 204 | |
dc.description.index | WoS | |
dc.description.index | Scopus | |